Amend

GetSwift Reports Fiscal Second Quarter 2022 Financial Results

Retrieved on: 
Monday, February 14, 2022
Data Management, Technology, Telecommunications, Software, Networks, Internet, Adoption, Parliamentary Information and Communication Technology Service, Data, Private sector, CEO, CTS, NEO Exchange, Amend, Churn, Contract, SEDAR, Pandemic, Corporation, Pressure, GSW, Intention, Technology, Risk, Compliance, Workforce, Mission statement, Automation, Data management, Growth, Cloud communications, COVID-19, News, NEO, Software as a service, LDA, Animal, Video game, Audit, Cryptocurrency, Risk management

GetSwift Technologies Limited ("GetSwift" or the "Corporation"; NEO: GSW), a leading provider of last mile SaaS logistics technology and services, has reported its financial and operational results for the fiscal second quarter of 2022 which ended December 31, 2021.

Key Points: 
  • GetSwift Technologies Limited ("GetSwift" or the "Corporation"; NEO: GSW), a leading provider of last mile SaaS logistics technology and services, has reported its financial and operational results for the fiscal second quarter of 2022 which ended December 31, 2021.
  • First fiscal half revenue totaled $20.5 million vs. $19.8 million for the full fiscal year in 2021
    Our growth accelerated in the second fiscal quarter of 2022, thanks to continued adoption of our products and services by major businesses that require affordable, scalable, and secure solutions, said Bane Hunter, CEO of GetSwift.
  • Total operating expenses for the second quarter of 2022 were $9.1 million as compared to total operating expenses of $2.8 million for the second quarter of fiscal 2021.
  • Total comprehensive loss for the second quarter of 2022 was $7.5 million, as compared to a total comprehensive loss of $5.4 million for the second quarter of fiscal 2021.

Delcath Appoints Anthony Dias as its new Vice President of Finance; Inducement Grant Reported

Retrieved on: 
Monday, February 7, 2022
Initial public offering, Arthur Andersen, GLOBE, Senior, IIB, Employment, Mother, Amend, Company, Melphalan, SeaChange, Sale, VP, FDA, Technology, Liver, CEO, LeMaitre Vascular, PHP, Mum, Nasdaq, CRO, Accounting, Treasury, Controller, PAREXEL, Finance, Delcath Systems

Mr. Diasbrings over 20 years of experience leading finance and operational teams at pharmaceutical, medical device and technology companies.

Key Points: 
  • Mr. Diasbrings over 20 years of experience leading finance and operational teams at pharmaceutical, medical device and technology companies.
  • Mr. Dias will oversee all financial aspects of the company, including financial planning and analysis, financial reporting, accounting and control, tax, and treasury.
  • Mr. Dias is a certified public accountant and worked at Arthur Andersen, a multinational professional services firm.
  • In connection with the appointment, Delcath has granted an equity award to Mr. Anthony Dias, Delcaths Vice President of Finance, outside of the Company's Amended and Restated 2020 Stock Incentive Plan and material to Mr. Dias acceptance of employment with the company.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, February 1, 2022
Private Securities Litigation Reform Act, Forward-looking statement, YouTube, Patient, Amyotrophic lateral sclerosis, SAN, ALS, Pharmacology, Cytokinetics, Twitter, Cohort, Research, Amend, Facebook, Employment, Mechanics, Company, Heart failure, GLOBE, HCM, Industry, LinkedIn, History, Hypertrophic cardiomyopathy, Muscle weakness, Cyprus Securities and Exchange Commission, Pharmaceutical industry, Public relations

Cytokinetics is also developing aficamten, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM).

Key Points: 
  • Cytokinetics is also developing aficamten, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM).
  • Cytokinetics is conducting start-up activities for SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with obstructive HCM.
  • Examples of such statements include, but are not limited to, statements relating toCytokinetics'and its partners' research and development activities of Cytokinetics product candidates.
  • CYTOKINETICS and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

ODD BURGER CORPORATION FILES AMENDED INTERIM MD&A FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2021

Retrieved on: 
Wednesday, January 26, 2022
ODD, View, Automation, Ontario Securities Commission, Disclosure, SEDAR, Cooking, Intention, TSX Venture Exchange, Crave, Amend, OSC, OTCQB, Multimedia, FSE, Food technology, Burger, Mission statement, Company, File, Technology, National instrument, Exchange, Audit, Tax advisor

TORONTO, Jan. 26, 2022 /PRNewswire/ - Odd Burger Corporation ("Odd Burger" or the "Company") (TSXV: ODD) (OTCQB: ODDAF) (FSE: IA9) today announced it has amended and refiled its management's discussion and analysis for the interim period ended June 30, 2021 (the "Amended MD&A"), to better comply with National Instrument 51-102 - Continuous Disclosure Obligations.

Key Points: 
  • TORONTO, Jan. 26, 2022 /PRNewswire/ - Odd Burger Corporation ("Odd Burger" or the "Company") (TSXV: ODD) (OTCQB: ODDAF) (FSE: IA9) today announced it has amended and refiled its management's discussion and analysis for the interim period ended June 30, 2021 (the "Amended MD&A"), to better comply with National Instrument 51-102 - Continuous Disclosure Obligations.
  • The amended information relates only to the management's discussion and analysis for the relevant periods, and no changes were made to the financial statements for the corresponding periods.
  • The Amended MD&A are available under the Company's profile on SEDAR at www.sedar.com .
  • Odd Burger Corporation is traded on the TSX Venture Exchange under the symbol ODD and on the OTCQB under the symbol GBLYF.

ENTRÉE RESOURCES WELCOMES START OF OYU TOLGOI UNDERGROUND MINE AND ANNOUNCEMENT OF RENEWED PARTNERSHIP WITH GOVERNMENT OF MONGOLIA

Retrieved on: 
Tuesday, January 25, 2022
COVID-19, Risk, Water, Coronavirus, ETG, Hugo, TSX, Industry, Mining, Partnership, Amend, Insurance, Private Securities Litigation Reform Act, SSD, Video news release, News, Rio Tinto, Lifting, Legislation, Transport, Copper, Heads of Agreement, Phrase, Company, Electrical energy, Silver, Technical report, Gold, Panel, Environment, Canadian Securities Administrators, Accident, Health, Conversation, Oyu Tolgoi mine, CEO, Treaty of friendship and alliance between the Government of Mongolia and Tibet, Oil, Bank, Risk management, BC, Turquoise Hill Resources, Agreement, Entré

The Oyu Tolgoi LLC ("OTLLC") board approved the signing of an Electricity Supply Agreement to provide Oyu Tolgoi with a long-term source of power from the Mongolian grid on terms fully agreed with the Government of Mongolia.

Key Points: 
  • The Oyu Tolgoi LLC ("OTLLC") board approved the signing of an Electricity Supply Agreement to provide Oyu Tolgoi with a long-term source of power from the Mongolian grid on terms fully agreed with the Government of Mongolia.
  • As a result, the OTLLC board unanimously approved commencement of the undercut to start Hugo North Lift 1 Panel 0 underground mine production on the Oyu Tolgoi mining licence.
  • Oyu Tolgoi includes two separate land holdings: the Oyu Tolgoi mining licence, which is held by Entre's joint venture partner, OTLLC, and the Entre/Oyu Tolgoi JV Property, a partnership between Entre and OTLLC.
  • Stephen Scott, Entre's President & CEO commented, "This is great news for Entre and all Oyu Tolgoi project stakeholders.

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, January 18, 2022
Health, Pharmaceutical, Amend, Patient, Arena Pharmaceuticals, International, Private Securities Litigation Reform Act, Financial compensation, Medication, Professional Football Compensation Committee, U.S. Securities and Exchange Commission, Nasdaq, Employment, RSU, Security (finance), Senior, Board, Management, Public relations

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement restricted stock units ("RSUs") to new employees.

Key Points: 
  • Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement restricted stock units ("RSUs") to new employees.
  • The inducement RSUs have a grant date and vesting commencement date of January 15, 2022 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The inducement RSUs are subject to the terms and conditions of Arena's Amended and Restated 2021 Long-Term Incentive Plan.
  • ARENA Pharmaceuticals is a team with a singular purpose deliver important medicines to patients.

Digihost Reports a Record 172 Bitcoins Mined in Q4 2021 in Addition to a 328% Increase in Q4 Y/Y Bitcoin Production and Announces Restatement of Q3 2021 Financial Statements

Retrieved on: 
Wednesday, January 12, 2022
Bitcoin, Income, Amend, RSU, Public Service Commission, Accounting, Miner, EBITDA, Carbon, Mining, New, Review, Tax, Consultant, NY, Company, MD, Interim, Mission statement, Acquisition, Cryptocurrency, Audit, Life insurance

As of December 31, 2021, approximately 6,500 of those Miners had been received.

Key Points: 
  • As of December 31, 2021, approximately 6,500 of those Miners had been received.
  • 100% of the Miners subject to that lease agreement are expected to be in service by the end of Q1 2022.
  • This deferred tax provision is an estimate of potential future taxes payable with the timing of payment being indeterminable as of September 30, 2021.
  • The Company has sufficient tax attributes available to offset taxable income generated during the nine month period ended September 30, 2021.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, January 10, 2022
Amend, Forward-looking statement, Patient, Research, Muscle weakness, Multisystemic smooth muscle dysfunction syndrome, SAN, LinkedIn, Private Securities Litigation Reform Act, Cytokinetics, GLOBE, Mechanics, Cyprus Securities and Exchange Commission, Facebook, Heart failure, Industry, Pharmacology, HCM, Company, ALS, YouTube, Employment, Hypertrophic cardiomyopathy, Cohort, Twitter, Amyotrophic lateral sclerosis, Pharmaceutical industry, Public relations

Cytokineticsis a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised.

Key Points: 
  • Cytokineticsis a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised.
  • For additional information aboutCytokinetics, visit www.cytokinetics.com and follow us on Twitter , LinkedIn , Facebook and YouTube .
  • Examples of such statements include, but are not limited to, statements relating toCytokinetics'and its partners' research and development activities of Cytokinetics product candidates.
  • CYTOKINETICS and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Myomo Amends China Joint Venture Agreement, Executes Technology and Trademark License Agreement

Retrieved on: 
Wednesday, January 5, 2022
Software, Physical Therapy, Hardware, Health, Medical Devices, Technology, Other Technology, Other Health, JV, Amend, Brachial plexus injury, Company, Patient, Arm, Stroke, NYSE, Lists of diseases, Technology transfer, Ascending limb of loop of Henle, Risk, U.S. Securities and Exchange Commission, Security (finance), Private Securities Litigation Reform Act, CEO, EMG, Compliance, Neuromuscular disease, Technology, ALS, CVA, Effective date, Paralysis, Pharmaceutical industry

The Amended JV Agreement, the Technology License Agreement and the Trademark License Agreement are each effective December 29, 2021 (the Effective Date).

Key Points: 
  • The Amended JV Agreement, the Technology License Agreement and the Trademark License Agreement are each effective December 29, 2021 (the Effective Date).
  • The original Joint Venture Agreement was entered into on January 21, 2021.
  • Under the Amended JV Agreement, Myomo will continue to own a 19.9% stake in the JV Company.
  • The technology transfer to the JV Company will begin after receipt of the full license fee, which is expected before the end of the first quarter of 2022.

MySize Announces Partial Adjournment of Annual Meeting of Stockholders

Retrieved on: 
Thursday, December 30, 2021
Twitter, Amend, Annual Meetings of the International Monetary Fund and the World Bank Group, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Annual general meeting, Proxy statement, Name, DIY, Instagram, Investor relations, Company, Forward-looking statement, Algorithm, THE, NASDAQ, IOS, Risk, SEC, Proxy, 2018 Michigan Proposal 3, Annual, TASE, Security (finance), LinkedIn, Android, Technology, Telephone, Online shopping, Facebook, Shareholder

The Company has adjourned the Annual Meeting solely with respect to Proposal 3 to provide its stockholders additional time to vote on Proposal 3.

Key Points: 
  • The Company has adjourned the Annual Meeting solely with respect to Proposal 3 to provide its stockholders additional time to vote on Proposal 3.
  • The record date for determining stockholders eligible to vote at the Annual Meeting will remain the close of business on November 4, 2021.
  • Stockholders who have already submitted a proxy do not need to vote again for the reconvened Annual Meeting, as the proxies submitted will remain valid.
  • Your vote will be recorded at the Annual Meeting in accordance with your most recently submitted proxy.